Euro 40m for Ablynx
Ghent – The Belgian nanobody-specialist Ablynx NV has raised a40 million in a series C round led by KBC. SR One, Abingworth, Alta Partners, Biotech Fund Flanders, Gilde, GIMV, Sofinnova Partners and VIB also participated in the round. Ablynx develops Nanobodies that are functional antigen-binding domains derived from an antibody's heavy chain. The company has three programs in preclinical testing, among them an injectible nanobody to treat rheumatoid arthrtis (RA) and an oral nanobody to treat inflammatory bowel disease.